Rafael Holdings, Inc.
No financial data available for RFL.
Company may not file with SEC or CIK is unresolved.
Rafael Holdings reported Q3 fiscal 2026 net loss of $0.08 per share on $4.2 million loss as it advances NPC drug toward NDA submission in H2 2026
“We believe we have a clear and expedited path forward reflective of the urgency and unmet need in NPC and expect to submit our NDA in the second half of calendar 2026.”
No Form 4 transactions on record.
Informational purposes only, not investment advice.